Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Executive Chairman

Chief Executive Officer

General Counsel and Secretary

Chief Physician Executive

Chief Financial Officer

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory dise...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	Executive Chairman
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2023-11-09	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-11-09	Premium	back to issuer	Premium	Premium	Premium	General Counsel and Secretary
2023-11-09	Premium	sold	Premium	Premium	Premium	-
2023-07-01	Premium	acquired	Premium	Premium	Premium	General Counsel and Secretary
2021-12-17	Premium	acquired	Premium	Premium	Premium	-

EQRX - EQRx, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for EQRX